KyungDong Pharm home
Prescription Medicines

S-Amlosyl Tab. 5mg

Product Category
CCB blood pressure lowering drugs
Active Ingredients
S-amlodipine besylate dihydrate
Appearance
A white, octagonal tablet.
Reimbursement Code
648104830
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: S-amlodipine besylate dihydrate (in-house specification) ---------- 7.38mg (5mg as es-amlodipine)
- Additives (animal origin): Anhydrous lactose (cow, milk), lactose hydrate (cow, milk)
- Other additives: microcrystalline cellulose, magnesium stearate, colloidal silicon oxide, croscarmellose sodium

2. Efficacy/Effectiveness
1. Myocardial ischemia caused by hypertension, fixed occlusion of the coronary artery (stable angina), or vasospasm of the coronary vasculature (atypical angina)
2. Patients with coronary heart disease recently confirmed by angiography and who do not have heart failure or an ejection fraction less than 40%
- Reduced risk of hospitalization due to angina pectoris
- Reduced risk of coronary artery revascularization

3. Usage/Dosage
Take this medicine with plenty of water.
Adults: As es-amlodipine, 2.5 mg is administered orally once a day, and the dose can be increased up to 5 mg per day depending on the patient's response. Increase or decrease appropriately depending on symptoms.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug, its components, or other dihydropyridine drugs (amlodipine is a dihydropyridine calcium channel blocker)
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with shock (including cardiogenic shock)
4) Patients with severe aortic stenosis
5) Patients with unstable angina pectoris
6) Patients within 1 month after myocardial infarction
7) Patients with severe liver dysfunction
8) Patients with severe low blood pressure
9) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with severe renal dysfunction (including patients with renal failure requiring dialysis)
2) Elderly people
3) Patients with acute heart failure
4) Patients with hypertensive crisis
5) Patients with mild to moderate liver dysfunction

3. Adverse reactions
1) Amlodipine is well tolerated. In placebo-controlled clinical trials on patients with hypertension and angina pectoris, the most common adverse reactions were as follows.
(1) Autonomic nervous system: Flushing accompanied by heat (especially at the beginning of treatment)
(2) Whole body: fatigue, swelling
(3) Cardiovascular system: Increased frequency, time, and severity of angina in patients with palpitations, at the beginning of treatment or when increasing dose (especially in patients with obstructive coronary artery disease)
(4) Central and peripheral nervous system: dizziness, headache (especially at the beginning of treatment), migraine, asthenia
(5) Digestive system: abdominal pain, nausea, indigestion
(6) Mental system: drowsiness
(7) Musculoskeletal system: ankle edema
In clinical trials, no clinically significant laboratory abnormalities related to amlodipine were observed.
2) Adverse reactions observed with relatively low frequency after marketing are as follows.
(1) Autonomic nervous system: dry mouth, increased sweating
(2) Whole body: weakness, malaise, pain, weight gain/loss, chills
(3) Cardiovascular system: hypotension, postural hypotension, postural dizziness, peripheral ischemia, vasculitis, syncope, tachycardia, peripheral edema
(4) Central and peripheral nervous system: hypertonia, hypoesthesia/paresthesia, peripheral neuropathy, dysgeusia, tremor, paralysis, extrapyramidal disorder
(5) Reproductive system: erectile dysfunction, gynecomastia
(6) Digestive system: Changes in bowel habits, indigestion, gastritis, gingival thickening, pancreatitis, vomiting, satiety, loss/increased appetite, dysphagia, abdominal bloating.
(7) Metabolism/Nutrition: Hyperglycemia, thirst, increased serum cholesterol, increased creatine kinase (CK)
(8) Musculoskeletal system: arthralgia, back pain, muscle cramps, muscle pain, increased skeletal muscle tension, arthrosis, monocontraction, ataxia, back pain
(9) Blood and lymphatic system: As leukopenia and thrombocytopenia may occur, sufficient observation should be conducted, including tests, and if abnormalities are recognized, administration should be discontinued and appropriate measures should be taken.
(10) Mental system: insomnia, mood changes, sexual dysfunction, dream abnormalities, depersonalization, apathy, nervousness, memory loss, sensitivity, depression, anxiety, confusion, fear, dysphoria
(11) Respiratory system: cough, difficulty breathing, rhinitis, nosebleeds
(12) Skin and subcutaneous tissue: hair loss, purpura, skin discoloration, urticaria, photosensitivity reaction, rash, erythema rash, maculopapular rash, cold and moist skin, telangiectasia, rash, itching, angioedema, toxic epidermal necrolysis.
(13) Sensory system: Tinnitus, visual abnormality, conjunctivitis, double vision, eye pain, dry eyes, smell abnormality, taste abnormality, decreased vision
(14) Urinary system: increased urination frequency, urinary disorder, enuresis, polyuria, pain during urination
(15) Hepatobiliary system: Hepatitis, jaundice, and elevated liver enzyme levels were reported very rarely, and most of these were related to cholestasis. Some cases that were severe enough to require hospitalization were reported to be related to the use of amlodipine, but in most cases, the causal relationship with amlodipine is unclear. If there are clinical signs of liver dysfunction (e.g., asthenia, anorexia, prolonged nausea), measurement of liver enzyme levels is recommended. If the level rises and jaundice appears, discontinue administration and take appropriate measures.
(16) Rarely, allergic reactions including itching, rash, angioedema, erythema multiforme, exfoliative dermatitis, and mucocutaneous ocular syndrome (Steven-Johnson syndrome) have been reported. If such hypersensitivity reaction occurs, discontinue administration.
3) As with other calcium channel blockers, the following adverse reactions were rarely reported, but it was not possible to distinguish whether they were caused by the underlying disease or the drug.
- Myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia, atrial fibrillation, extrasystoles, atrial arrhythmia), chest pain
4) Other adverse reactions as follows were observed.
(1) Cardiovascular system: Occasionally, a drop in blood pressure, sinoatrial or atrioventricular block, and rarely abdominal discomfort may occur. If atrioventricular block occurs, discontinue administration and take appropriate measures.
(2) Digestive system: Occasionally, abdominal pain, diarrhea, loose stools, constipation, etc. may occur.
(3) Skin: In rare cases, redness of the skin and spotty-papular rash may appear.
(4) Others: Occasionally, heaviness, hot flashes, decreased glucose tolerance, and weakness may occur.

4. General precautions
1) Cases of worsening symptoms have been reported when calcium channel blocker administration was abruptly stopped, so if a medication break is necessary, reduce the dose slowly and observe thoroughly. Also, caution patients not to stop taking medication without doctor's instructions.
2) Administration to patients with heart failure: In a long-term, placebo-controlled trial (PRAISE-2) of amlodipine in patients with NYHA class III and IV heart failure without ischemic etiology, this drug was associated with an increase in reports of pulmonary edema despite no significant difference in the rate of worsening heart failure compared to placebo.
3) Administration to patients with liver dysfunction: Like all calcium channel blockers, the half-life of amlodipine is prolonged in patients with liver dysfunction, and the recommended dosage for these patients has not been established. Therefore, these patients should be administered with caution.
4) Because the plasma concentration half-life is long, a gradual blood pressure lowering effect appears even after discontinuation of administration. Therefore, when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
5) Since the effect appears slowly, it cannot be expected to be effective in unstable angina pectoris that requires emergency treatment.
6) Take this medicine with a sufficient amount of water.
7) Because the blood pressure lowering effect may cause dizziness, etc., be careful when operating dangerous machinery such as working at heights or driving a car. Use caution in patients with dizziness, headache, fatigue, or nausea as their ability to respond may be impaired.

5. Interaction
1) Amlodipine is safe when used in combination with thiazide diuretics, alpha-blockers, beta-blockers, ACE inhibitors, long-acting nitrate agents, nitroglycerin sublingual tablets, NSAIDs, antibiotics, and oral hypoglycemic agents.
2) Laboratory data using human plasma show that amlodipine does not affect the protein binding of digoxin, phenytoin, warfarin, and indomethacin.
3) Grapefruit juice: A single co-administration of 240 mL of grapefruit juice and 10 mg of amlodipine in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine. In this study, the impact of genetic polymorphisms in CYP3A4, the main metabolic pathway for amlodipine, was not evaluated. Therefore, co-administration of amlodipine with grapefruit or grapefruit juice may increase the blood pressure lowering effect in some patients due to increased bioavailability, so co-administration is not recommended.
4) Dantrolene (injection): In animal experiments where verapamil and dantrolene were administered through IV, fatal ventricular spasms were consistently observed. Simultaneous administration of amlodipine and dantrolene should be avoided.
5) Baclofen: As it increases the blood pressure lowering effect, administer with caution regarding blood pressure and dosage if necessary.
6) Clarithromycin: Clarithromycin is a cytochrome P3A4 inhibitor. The risk of hypotension increased when clarithromycin was coadministered with amlodipine.
It is recommended that patients be carefully observed when coadministering this drug and clarithromycin.
7) How other drugs affect amlodipine
(1) Cimetidine: There was no effect on the pharmacokinetics of amlodipine when administered in combination.
(2) Aluminum/magnesium (antacid): When administered in combination with aluminum/magnesium antacid and a single dose of amlodipine, there was no significant effect on the pharmacokinetics of amlodipine.
(3) Sildenafil: Administration of a single dose of 100 mg of sildenafil to patients with primary hypertension did not affect the pharmacokinetic parameters of amlodipine. When amlodipine and sildenafil are administered together, each drug exerts its own blood pressure lowering effect independently.
(4) Cytochrome P3A4 inhibitor: In elderly (69-87 years old) hypertensive patients, co-administration of 180 mg of diltiazem and 5 mg of amlodipine per day increased the systemic exposure of amlodipine by 57%. In healthy volunteers (18-43 years of age) co-administration of erythromycin did not significantly alter systemic exposure to amlodipine (22% increase in AUC). Although the clinical relevance of this has not been revealed, pharmacokinetic changes may be more evident in elderly people. The possibility that strong cytochrome P3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase plasma concentrations of amlodipine to levels higher than those seen with co-administration with diltiazem cannot be ruled out. Amlodipine should be administered with caution when administered in combination with cytochrome P3A4 inhibitors. However, no adverse reactions resulting from this drug interaction have been reported.
(5) CYP3A4 inducers: Co-administration with CYP3A4 inducers (e.g. rifampicin, St. John's wort (hypericum perforatum)) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
8) Effect of amlodipine on other drugs
(1) Atorvastatin: There was no significant change in the pharmacokinetic parameters of atorvastatin when 80 mg of atorvastatin and multiple doses of 10 mg of amlodipine were coadministered.
(2) Digoxin: When amlodipine and digoxin were co-administered to normal volunteers, there was no change in serum digoxin levels or digoxin renal clearance.
(3) Alcohol: There was no significant change in the pharmacokinetics of alcohol during single or repeated administration of 10 mg amlodipine.
(4) Warfarin: When amlodipine and warfarin were administered together, there was no effect on the warfarin-prothrombin reaction time.
(5) Cyclosporine: In several studies in which cyclosporine and amlodipine were administered together in kidney transplant patients, it was reported that the trough blood concentration of cyclosporine remained unchanged or increased by up to 40% when administered in combination with amlodipine.
(6) Tacrolimus: When administered in combination with this drug, there is a risk of increasing the blood concentration of tacrolimus. Therefore, when administering this drug to patients being treated with tacrolimus, the blood concentration of tacrolimus should be monitored and the dosage of tacrolimus should be appropriately adjusted to avoid tacrolimus toxicity.
(7) mTOR inhibitors: mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus) are substrates of CYP3A. Amlodipine is a weak CYP3A inhibitor, and when coadministered with mTOR inhibitors, amlodipine may increase exposure to mTOR inhibitors.
(8) Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased the exposure of simvastatin by approximately 77% compared to administration of simvastatin alone. In patients receiving amlodipine, the maximum daily dose of simvastatin is up to 20 mg.
9) Other blood pressure lowering drugs: When used in combination with other blood pressure lowering drugs, the blood pressure lowering effect may be increased. In particular, caution should be exercised as the combined use of calcium channel blockers and beta blockers can cause heart failure, low blood pressure, and even myocardial infarction.
10) Tricyclic antidepressants: May increase blood pressure lowering effect.
11) Nitrate preparations: May increase the effect of this drug on blood pressure and heart rate.
12) Antiarrhythmic drugs (amiodarone, quinidine, etc.): The inhibitory effect on muscle contraction may increase.
13) Theophylline and ergotamine: Calcium channel blockers may interfere with the metabolism of theophylline and ergotamine, which depends on CYP-450 metabolism. When taking this medicine together, it is recommended to check blood regularly.

6. Administration to pregnant and lactating women
1) The safety of this drug for pregnant women has not been established. Delayed and prolonged labor was observed in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended human dose. Additionally, during animal testing, high doses of amlodipine showed reproductive toxicity.
2) The safety of this drug for nursing mothers has not been established. Therefore, stop breastfeeding while taking this medicine. In human administration experience, it has been reported that amlodipine passes into human breast milk.

7. Administration to children
Amlodipine (2.5 mg-5 mg per day) is effective in lowering blood pressure in patients aged 6 to 17 years. The effect of amlodipine on blood pressure in patients younger than 6 years of age is unknown.

8. Administration to elderly people
In general, excessive lowering of blood pressure is not desirable for elderly people. In the case of the elderly, the blood concentration of the drug increases and the half-life tends to become longer, so administer with caution while observing the patient's condition, such as starting from a low dose.

9. Treatment in case of overdose
Current data indicate that severe overdose may result in reflex tachycardia along with excessive peripheral vasodilation. In addition, systemic hypotension, flushing, headache, reflex tachycardia, heart rate abnormalities, and cardiovascular blood circulation abnormalities can lead to shock, unconsciousness, and coma. The absorption of amlodipine was significantly reduced when activated charcoal was administered immediately or up to 2 hours after administering 10 mg of amlodipine to healthy volunteers. In some cases, gastric lavage may be useful. Clinically serious hypotension caused by overdose of this drug requires active supportive treatment for the cardiovascular system, such as frequent monitoring of heart and respiratory function, maintaining the position of the limbs higher than the body, and ensuring sufficient circulating fluids such as blood and urine excretion. Unless there are special cases where the use of vasoconstrictors is contraindicated, vasoconstrictors may be useful in restoring vascular tone and blood pressure. Intravenous administration of calcium gluconate may be useful in reversing the effects of calcium channel inhibitors. Because amlodipine has a very high protein binding rate, hemodialysis is not helpful.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Preclinical data
1) Carcinogenicity
There was no evidence of carcinogenicity in rats and mice administered amlodipine at doses of 0.5, 1.25, and 2.5 mg/kg/day for 2 years. In addition, the highest dose administered in this experiment was close to the maximum tolerated dose in mice (a dose close to the maximum recommended clinical dose of 10 mg on a mg/m2 basis in mice, and twice the maximum recommended clinical dose in rats*)
2) Mutability
In mutation tests, the drug had no effect on gene or chromosome levels.
3) Fertility abnormalities
In rats (treated for 64 days for males and 14 days for females before mating) treated with amlodipine at doses up to 10 mg/kg/day (8 times the maximum recommended clinical dose of 10 mg on a mg/m2 basis*), no effect on fertility was observed.
*: Based on patient weight of 50 kg

12. Pharmaceutical equivalence test information**
A. A 2×2 cross-over study was conducted between the test drug Es-amlodipine besylate dihydrate 5 mg (Samchun Dang Pharmaceutical Co., Ltd.) and the reference drug Levotension Tablets 2.5 mg (Anguk Pharmaceutical Co., Ltd.). One tablet of the test drug and two tablets of the reference drug were administered orally once on an empty stomach to healthy adults. As a result, amlodipine in the blood of 31 people was measured. The comparative evaluation item values (AUCt, Cmax) were converted to logarithm and processed for statistical processing. When this was done, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
* Table: refer to manual
**This drug was manufactured by Samchundang Pharmaceutical Co., Ltd. using the same raw materials as 2.5 mg amlodipine besylate dihydrate tablets, using the same manufacturing method, and all processes were outsourced to Samchundang Pharmaceutical Co., Ltd.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 300 tablets/bottle

7. Expiration date
24 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1S-Amlosyl Tab. 5mgPrecautions for use2023.07.24S-Amro Facts_Precautions for use.pdfFile under review